Affimed (NASDAQ:AFMD) – Stock analysts at Truist Securiti increased their FY2021 earnings per share (EPS) estimates for shares of Affimed in a research report issued to clients and investors on Monday, November 22nd. Truist Securiti analyst S. Devarakonda now forecasts that the biopharmaceutical company will earn ($0.53) per share for the year, up from their previous forecast of ($0.54). Truist Securiti also issued estimates for Affimed’s FY2022 earnings at ($0.90) EPS, FY2023 earnings at ($1.11) EPS and FY2024 earnings at ($0.81) EPS.
A number of other analysts also recently issued reports on the stock. SVB Leerink restated a “buy” rating and set a $12.00 price target on shares of Affimed in a report on Sunday, November 14th. Zacks Investment Research upgraded shares of Affimed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 14th. Berenberg Bank assumed coverage on shares of Affimed in a research report on Wednesday, November 17th. They set a “buy” rating for the company. Stifel Nicolaus assumed coverage on shares of Affimed in a research report on Wednesday, September 29th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Truist assumed coverage on shares of Affimed in a research report on Thursday, October 21st. They set a “buy” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.13.
Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Wednesday, November 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). Affimed had a negative return on equity of 40.23% and a negative net margin of 132.18%. During the same quarter last year, the company posted ($0.08) EPS.
Hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. purchased a new position in Affimed in the 2nd quarter valued at approximately $71,000. HighTower Advisors LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $85,000. Schonfeld Strategic Advisors LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $88,000. Boothbay Fund Management LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $90,000. Finally, Lindbrook Capital LLC boosted its position in Affimed by 30.0% in the 2nd quarter. Lindbrook Capital LLC now owns 11,700 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 2,700 shares during the period. 73.02% of the stock is owned by institutional investors.
Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.
Further Reading: Quantitative Easing
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.